FOXNews.com: Sanofi cancer drug gets FDA fast-track for colon cancer

FOXNews.com FOX News Network - We Report. You Decide. // via fulltextrssfeed.com

Sanofi cancer drug gets FDA fast-track for colon cancer Apr 5th 2012, 12:05 Sanofi and its US-based partner Regeneron Pharmaceuticals said Thursday their experimental drug Zaltrap missed targeted goals in a late-stage clinical trial for treating prostate cancer but that US regulators are giving it a fast-track review for use in treating colon cancer. Sanofi said the Phase III VENICE trial involving 1,226 prostate cancer patients "did not meet the pre-specified criterion of improvement in overall survival." The French drug maker added that the US Food and Drug Administration (FDA) had granted a priority review to the companies to examine Zaltrap in the treatment of colon cancer. That filing is based on a late-stage study, called VELOUR, in patients with colorectal cancer, whose disease has spread to other parts of the body and who have been previously treated with an oxaliplatin-containing regimen. A fast-track priority review is given to drugs if preliminary estimates indicate that the product, if approved, has the potential to provide a treatment where no adequate therapy exists or it shows significant improvement compared with marketed products. The FDA is due to give a decision on its Zaltra priority review by Aug. 4.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions